Goldman Sachs
BBNX icon

Goldman Sachs’s Beta Bionics BBNX Stock Holding History

Goldman Sachs’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.42M Buy
537,105
+415,771
+343% +$4.94M ﹤0.01% 3409
2026
Q1 		$1.22M Sell
121,334
-284,074
-70% -$4.2M ﹤0.01% 4952
2025
Q4 		$12.4M Buy
405,408
+6,155
+2% +$164K ﹤0.01% 2881
2025
Q3 		$7.93M Buy
399,253
+88,252
+28% +$1.55M ﹤0.01% 3198
2025
Q2 		$4.53M Buy
311,001
+252,579
+432% +$3.58M ﹤0.01% 3524
2025
Q1 		$715K Buy
+58,422
New +$1.09M ﹤0.01% 4942

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Goldman Sachs's BBNX Position: Q2 2026 in Review

Goldman Sachs increased its Beta Bionics (BBNX) stake by 343% in Q2 2026, buying an estimated $4.94M and bringing the position to 537,105 shares worth $8.42M. The position accounts for ﹤0.01% of the portfolio, ranked #3409.

Goldman Sachs first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $12.4M in Q4 2025. 133 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Goldman Sachs held 537,105 shares of Beta Bionics worth $8.42M as of Q2 2026.
  • Goldman Sachs bought 415,771 Beta Bionics shares in Q2 2026, an estimated $4.94M.
  • Beta Bionics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #3409 holding.
  • Goldman Sachs first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • Goldman Sachs's Beta Bionics position peaked at $12.4M in Q4 2025.
  • 133 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.